Esperion Therapeutics Inc (ESPR) Return on Equity ROE from the first quarter 2026 to first quarter 2025 and annually, average high and low, overall ranking from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Esperion Therapeutics Inc   (NASDAQ: ESPR)

Esperion Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Esperion Therapeutics Inc in the first quarter 2026?
Due to the lack of equity, it was not possible to calculate Esperion Therapeutics Inc 's return on equity (ROE) in its first quarter 2026

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -7 -23 -106 -104 -153
Return On Equity (TTM) - - - - -
ESPR's Total Ranking # # # # #
Equity (TTM) in Millions -308 -302 -451 -434 -426
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to ESPR Management Effectiveness >> ESPR's 5 Years Annual ROE >> Compare ESPR ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





ESPR Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions -302 -389 -455 -324 -197
Y / Y Equity Change - - - - -
Net Income in Millions -23 -52 -209 -234 -269
Y / Y Net Income Change - - - - -
Return On Equity - - - - -

Back to ESPR Management Effectiveness >> ESPR's 5 Years Annual ROE >> Compare ESPR ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ESPR's' Return on Equity at Yahoo Finance
ESPR's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ESPR's Competitors
Subscribers only: Roe for Esperion Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for ESPR's Customers




Companies with similar Return On Equity at Mar 31 2026, within Healthcare Sector ROE
Conmed Corporation  5.40 %
National Vision Holdings Inc   5.36 %
Fonar Corporation  5.26 %
Becton Dickinson And Company  4.53 %
Biomarin Pharmaceutical Inc  4.41 %
Organon and Co   3.89 %
Xtant Medical Holdings Inc   3.68 %
Privia Health Group Inc   3.54 %
Revvity Inc  3.26 %
Surgery Partners Inc   3.10 %
The Cooper Companies Inc   2.85 %
Artivion Inc   2.66 %
Repligen Corp  2.46 %
Bio rad Laboratories Inc   2.40 %
Icu Medical Inc  2.19 %
Envista Holdings Corporation  2.18 %
Radnet Inc   1.70 %
Lifestance Health Group Inc   1.56 %
Castle Biosciences Inc   1.04 %
Talkspace Inc   1.03 %
Pacira Biosciences inc   0.73 %
Jazz Pharmaceuticals Plc  0.71 %
Therapeuticsmd Inc   0.66 %
Delcath Systems Inc   0.51 %
Denali Therapeutics Inc   0.45 %

Date modified: 2026-09-18T13:11:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.